首页> 外文OA文献 >Prevalence, risk factors and outcomes of multidrug resistant Tuberculosis identified by GeneXpert MTB/RIF Assay in Bukavu, Democratic Republic of the Congoudud
【2h】

Prevalence, risk factors and outcomes of multidrug resistant Tuberculosis identified by GeneXpert MTB/RIF Assay in Bukavu, Democratic Republic of the Congoudud

机译:通过GeneXpert MTB / RIF分析在刚果民主共和国布卡武确定了耐多药结核病的患病率,危险因素和结果 ud ud

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Tuberculosis (TB) has been the top-ranked infectious disease in human history for a very long time. According to World Health Organization (WHO), Democratic Republic of the Congo (DRC) has been high HIV/TB co-infection burden area for decades. However, MDR-TB were underreported in DRC due to the incompetent healthcare infrastructure and the lack of diagnostic method. ududMethod: This study aims to provide more epidemiological information on the prevalence of multidrug resistant tuberculosis (MDR-TB) infection identified by GeneXpert MTB/RIF assay, which is a new diagnostic method. The data were collected at the General Referral Hospital of Bukavu, DRC. Subject population was the suspected TB patients who visited the hospital of Bukavu, DRC. Retrospective analyses were done based on those data to identify risk factors. In addition, multiple statistical analyses, including multivariate logistic regression, Pearson Chi-square test were performed to investigate how the TB prevalence and treatment outcomes relate to risk factors and GeneXpert assay. ududResults: The Prevalence of all TB in the study population is 15.6% as identified by GeneXpert Assay. MDR-TB prevalence is 3.2% among the whole study population and 20% among TB positive subgroup. Logistic regression showed that previous TB episode and HIV known status are risk factors for developing MDR-TB. However, no risk factor for treatment failure was found in this study.ud udConclusions: GeneXpert Assay provided reliable TB and MDR-TB prevalence data in the resource limited area Bukavu, DRC. We noticed that MDR-TB prevalence from our study is significantly higher than national level, which suggests severe underestimation of MDR-TB burden in DRC. However, loss to follow-up of treatment outcome and high proportion of HIV status unknown are significantly affecting the data validity of this study.ud udPublic Health Significance: The control of MDR-TB in DR Congo requires diagnostic methods that are not only easy to implement in resource limited area, but also fast in turnaround time for both TB infection and drug resistance detection. GeneXpert MTB/RIF assay is an ideal test, but lack of field test. This study provides solid evidence of the performance of GeneXpert assay in the field as a solution of MDR-TB underreported issue.ud
机译:背景:结核病(TB)在很长一段时间以来一直是人类历史上排名第一的传染病。根据世界卫生组织(WHO)的说法,刚果民主共和国(DRC)数十年来一直是艾滋病毒/结核病合并感染的重担区。然而,由于医疗基础设施不健全和缺乏诊断方法,刚果民主共和国的耐多药结核病报告不足。方法:本研究旨在提供有关通过GeneXpert MTB / RIF分析鉴定出的多药耐药结核(MDR-TB)感染率的流行病学信息,这是一种新的诊断方法。数据在刚果民主共和国布卡武总医院转诊。受试者人群是前往刚果民主共和国布卡武医院的可疑结核病患者。根据这些数据进行回顾性分析,以识别危险因素。此外,还进行了多种统计分析,包括多元逻辑回归,Pearson卡方检验,以调查结核病患病率和治疗结果与危险因素和GeneXpert分析之间的关系。 ud ud结果:通过GeneXpert分析确定,研究人群中所有结核病的患病率为15.6%。在整个研究人群中,MDR-TB患病率为3.2%,在TB阳性亚组中为20%。 Logistic回归表明,先前的结核病发作和艾滋病毒已知状况是发展耐多药结核病的危险因素。然而,在这项研究中没有发现治疗失败的危险因素。 ud ud结论:GeneXpert分析在资源有限的地区Duka Bukavu提供了可靠的TB和MDR-TB患病率数据。我们注意到,我们研究中的耐多药结核病患病率显着高于全国水平,这表明严重低估了刚果民主共和国的耐多药结核病负担。但是,对治疗结果的追踪失败以及艾滋病毒状况未知的比例很高,都严重影响了这项研究的数据有效性。 ud ud公共卫生意义:控制刚果民主共和国的耐多药结核病不仅需要诊断方法,易于在资源有限的区域中实施,而且在结核病感染和耐药性检测方面的周转时间也很快。 GeneXpert MTB / RIF分析是一种理想的测试方法,但缺乏现场测试。这项研究提供了GeneXpert检测作为解决MDR-TB少报问题的解决方案的现场证据。 ud

著录项

  • 作者

    Lu Yifeng;

  • 作者单位
  • 年度 2016
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号